Notícias e Atividades da Phathom Pharmaceuticals

Phathom Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Phathom Pharmaceuticals é uma empresa listada sob o símbolo PHAT (US).

Veja o organograma con seus 27 executivos principais

Biografias mais buscadas da Phathom Pharmaceuticals

• Steven Basta, President and Chief Executive Officer and Director
• Frank Karbe, Director
• Asit Parikh, Director

Recentes movimentos de executivos em Phathom Pharmaceuticals

• Ted Schroeder, ingressou na Companhia como Director  (Notícia publicada em 17 de abril de 2025).
• Terrie Curran, Director and Chief Executive Officer, deixou a Companhia  (Notícia publicada em 1 de abril de 2025).
• Steven Basta, ingressou na Companhia como President and Chief Executive Officer and Director  (Notícia publicada em 1 de abril de 2025).

Criar um alerta
para seguir os movimentos de executivos da Phathom Pharmaceuticals.

Phathom Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Phathom Pharmaceuticals

• Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022 | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults | Phathom Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Phathom Pharmaceuticals

• Phathom Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Phathom Pharmaceuticals na LinkedIn, Twitter e YouTube